Endometriosis diagnosis: New tech could fast-forward and revolutionize diagnosis for women

For millions of women, chronic pelvic pain, heavy periods, and endless fatigue aren’t just random annoyances — they’re everyday struggles. Yet, the real cause, endometriosis, is still one of the most overlooked and underdiagnosed issues in women’s health.On average, women wait four to eleven years to get answers. That’s not just frustrating; it can change everything about their lives. While they wait, endometriosis can sneakily get worse, mess with fertility, trigger mental health concerns, and tank quality of life.The good news is, there’s been a remarkable breakthrough that could flip the story of millions of women’s struggles.Researchers are rolling out new tech: AI-powered imaging, non-invasive scans, blood tests — all aimed at catching endometriosis early, without resorting to surgery. One scan using a new radiotracer is turning heads, because it spots endometriosis in ways older tools just can’t.For the first time, diagnosis could move from being uncertain and invasive to something way faster, safer, and clearer.What did the research find? What’s the new tech? How do we move forward?Let’s unpack.Endometriosis happens when tissue similar to your uterine lining starts growing outside the uterus: on the ovaries, fallopian tubes, or your pelvic walls. Each month, this rogue tissue acts just like your normal lining: thickening, breaking down, and bleeding. But the blood gets trapped, causing inflammation and scarring.It’s not rare. It’s not new. Yet somehow, it’s one of the toughest women’s health problems to diagnose.Now, this is where things get exciting.A recent trial tested a special imaging scan using a radiotracer called maraciclatide. Instead of searching for visible scars, the tracer locks onto new blood vessels, which is a hallmark of endometriosis. Once injected, the affected spots “light up” in scans, letting doctors actually see what’s going wrong in real time.And the results are pretty impressive. In the study, the scan matched surgical findings in 16 out of 19 patients, and there were no false positives.Best of all, it detected superficial endometriosis: the most common and tricky form to spot, often missed by typical scans.The study was led by Professors Becker and Zondervan. It was a small, open-label, single-center Phase 2 study using SPECT-CT scans and 99mTc-maraciclatide in 20 patients suspected of pelvic or thoracic endometriosis. The main focus was on how well scan findings matched surgical findings.Ten participants had prior ultrasounds or MRIs (none had spotted SPE). Phase III international studies are expected later this year.The Nuffield Department of Women’s & Reproductive Health at Oxford and Serac Healthcare announced their Phase 2 findings in The Lancet Obstetrics and Gynaecology. The results highlight the promise of their molecular imaging agent, 99mTc-maraciclatide, a non-invasive way to diagnose and monitor endometriosis.If this scan passes all the tests and is implemented, it could become the go-to test for superficial peritoneal endometriosis (SPE), which regular scans don't pick up and currently require surgery to diagnose. Better yet, it might let doctors monitor disease and catch recurrences and could help track how well treatments are working.99mTc-maraciclatide is a gamma-emitting radiotracer that binds to αvβ3 integrin, a protein that ramps up with new blood vessel growth — classic in inflammation. This is the first time it's been used to visualize and diagnose endometriosis.The DETECT study showed a strong correlation between scan results and surgical reports across all types of endometriosis, including SPE, which shows up in 80% of surgical cases. In fact, 99mTc-maraciclatide spotted endometriosis that normal imaging misses.Out of 19 cases, scans agreed with surgical findings in 16. They saw endometriosis in 14 out of 17 surgically positive cases, including two rare thoracic cases.There were no false positives — it worked across various subtypes and was well tolerated; patients liked it.Dr. Tatjana Gibbons (lead author, Oxford): "Maraciclatide looks like a powerful diagnostic and monitoring tool, especially for the most common — and hardest to spot — type."Professor Christian Becker (Co-director, Endometriosis CaRe Centre, Oxford): "Non-invasive tests for endometriosis are a top research priority. If we confirm these Phase II results in Phase III, maraciclatide could dramatically cut delays and provide a real benchmark for new therapies."David Hail (CEO, Serac Healthcare): "This study marks a turning point for us. With FDA Fast Track and Phase III studies lined up, we’re heading for wider trials and eventual approval."Professor Krina Zondervan (Oxford): "SPE is the most common type, but it's nearly impossible to spot without surgery. If Phase III confirms these results, maraciclatide could transform research and give women more options."For the unversed, endometriosis symptoms can be harsh or weirdly inconsistent.Many women report period pain way beyond anything “normal.” Others have constant pelvic aches, pain during sex, digestive issues, or mysterious fatigue. Infertility due to this condition is widespread. Oddly, some with mild symptoms have advanced disease, and others with early-stage endometriosis suffer badly.That randomness makes the symptoms easy to brush off, for both patients and doctors.Why does the diagnosis of endometriosis take so long?First of all, people start thinking painful periods are just “normal.” By the time women push for answers, the disease might be advanced. Secondly, endometriosis mimics other conditions, like IBS, hormone issues, or even regular period cramps. This leads to misdiagnoses and endless doctor visits.The toughest hurdle is the gold standard for diagnosis: laparoscopy, surgery that lets doctors see inside the abdomen. So, to get answers, you need an operation. Most people wait it out, doctors are cautious, and that drags things out.That’s not just stressful; it fundamentally changes lives. Untreated endometriosis gets worse, causing more pain and more lesions. It hits fertility, strains relationships, impacts work, and can leave patients feeling invisible in the healthcare system.That’s why this trial matters a great deal — if larger trials back up these results, this scan could rewrite the whole diagnostic process. Instead of waiting years and risking surgery, patients might get answers through a simple, safe test, which will bring huge relief to millions of women.Moreover, doctors could spot the disease faster, monitor progress without repeat surgery, and track treatment effectiveness, and researchers would get new ways to study endometriosis and develop better treatments.